Considerations for Dose Modifications

Author(s):

Kirollos Hanna, PharmD, BCPS, BCOPBrandon Dyson, PharmD, BCPS

The discussion addresses when dose modifications are typically required in chronic lymphocytic leukemia treatment and identifies the most common reasons for these modifications.

EP: 1.BTK Inhibitor-Associated Adverse Events

EP: 2.Managing Adverse Events and Supportive Care Measures in CLL Treatment

EP: 3.Impact of Dose Modifications on CLL Treatment

Now Viewing

EP: 4.Considerations for Dose Modifications

EP: 5.Economic Impact of Dose Modifications on CLL Management

EP: 6.Factors to Consider When Switching Therapies

Video content above is prompted by the following:

When do patients typically require dose modification in chronic lymphocytic leukemia (CLL) treatment, and what are the most common reasons for dose modifications in CLL treatments?